Stay updated on ONO-4538 in NSCLC Clinical Trial
Sign up to get notified when there's something new on the ONO-4538 in NSCLC Clinical Trial page.

Latest updates to the ONO-4538 in NSCLC Clinical Trial page
- Check6 days agoChange DetectedThe page footer’s software/UI revision indicator has been updated from “v3.5.2” to “v3.5.3,” reflecting an incremental site release rather than a change to the clinical study information.SummaryDifference0.0%

- Check14 days agoChange DetectedUpdated sponsor name from Ono Pharmaceutical Co. Ltd to Ono Pharmaceutical Co., Ltd and updated page revision from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check21 days agoChange DetectedPublication section updated: added full citation for Cancer Sci. 2026 (TASUKI-52 Four-Year Outcomes) and removed the online-ahead-of-print citation.SummaryDifference0.0%

- Check42 days agoChange DetectedSite revision updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check50 days agoChange DetectedA new plain-language TASUKI-52 publication (Future Oncol. 2026; Sugawara et al.) was added. The earlier online-ahead-of-print entry for this publication was removed.SummaryDifference0.0%

- Check78 days agoChange DetectedThe page now includes a plain language summary for TASUKI-52 describing nivolumab plus platinum chemotherapy and bevacizumab for NSCLC, and the revision was updated to v3.4.2. A government funding notice was removed.SummaryDifference0.2%

Stay in the know with updates to ONO-4538 in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ONO-4538 in NSCLC Clinical Trial page.